参考文献1.Kerr, and K. M . “Pulmonary preinvasive neoplasia.” Journal of Clinical Pathology 54.4(2001):257-271.2.Bray, Freddie , et al. “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.” CA: A Cancer Journal for Clinicians 68.6(2018).3.Re, Marzia Del , et al. “Implications of KRAS mutations in acquired resistance to treatment in NSCLC.” Oncotarget 9.5(2018):6630-6643.4.Campbell SL, Khosravi-Far R, et al. “Increasing complexity of Ras signaling” .Oncogene. 17(1998):1395–1413.5.Wennerberg, and K. “The Ras superfamily at a glance.” Journal of Cell Science 118.5(2005):843-846.6.Vigil, Dominico , et al. “Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?.” Nature Reviews Cancer 10.12(2010):842-857.7.Malkinson, and M. Alvin . “Molecular Comparison of Human and Mouse Pulmonary Adenocarcinomas.” Experimental Lung Research 24.4(1998):541-555.8.Downward, and Julian. “Targeting RAS signalling pathways in cancer therapy.” Nature Reviews Cancer 3.1(2003):11-22.9.Ihle, N. T. , et al. “Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome.” JNCI Journal of the National Cancer Institute 104.3(2012):228-239. 10.Grabocka, Elda , and D. Bar-Sagi . “Mutant KRAS Enhances Tumor Cell Fitness by Upregulating Stress Granules.” Cell 167.7(2016):1803-1813.e12.11.Villanueva, A. , et al. “Diagnostic utility of K-ras mutations in fine-needle aspirates of pancreatic masses.” Gastroenterology 110.5(1996):1587-1594.12.Sun, C , et al. “Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines. ” Oncology Reports 8.1(2001):89–92.13.Golan, Talia , et al. “RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients.” Oncotarget 6.27(2015).14.Soussi T, Béroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nature Reviews Cancer. 1.3(2001):233-240.15.Hernandez-Boussard, Tina , et al. “IARC p53 mutation database: A relational database to compile and analyze p53 mutations in human tumors and cell lines.” Human Mutation 14.1(1999):1-8.16.Li, Da Hu , L. Q. Zhang , and F. C. He . “[Advances on mutant p53 research].” Hereditas (Beijing) 30.6(2008):697-703.17.Sigal, Alex , and V. Rotter . “Oncogenic Mutations of the p53 Tumor Suppressor: The Demons of the Guardian of the Genome.” Cancer Research 60.24(2000):6788-6793.18.Trkova, Marie , et al. “A Li-Fraumeni syndrome family with retained heterozygosity for a germline TP53 mutation in two tumors.” Cancer Genetics and Cytogenetics 145.1(2003):60-64.19.Kastan, Michael B , and E. Berkovich . “p53: a two-faced cancer gene. ” Nature Cell Biology 9.5(2007):489-91.20.Eliyahu D, Goldfinger N, Pinhasi-Kimhi O, et al. Meth A fibrosarcoma cells express two transforming mutant p53 species. Oncogene, 3.3 (1988):313-2121.Johnson, Leisa , et al. “Somatic activation of the K-ras oncogene causes early onset lung cancer in mice.” Nature 410.6832(2001):1111-1116.